Target intelligence / Profile preview

Long intergenic non-protein coding RNA 680 (LINC00680)

Target
LINC00680
Molecular classification
Long non-coding RNA (lncRNA), Non-protein coding transcript, Other
01

Overview

Long intergenic non-protein coding RNA 680 (LINC00680) is a human long non-coding RNA located on chromosome 6 (HGNC:44417), characterized by its lack of protein-coding potential[5][9]. It acts primarily as a competing endogenous RNA (ceRNA), regulating the activity of several microRNAs including miR-320a and miR-320b, thus modulating the expression of key genes involved in cell proliferation, apoptosis, and immune responses (e.g., MAPK1 and EGR3)[2][4][6]. Elevated levels of LINC00680 are associated with increased disease severity in myasthenia gravis and are implicated in tumor progression in cancers such as glioblastoma and esophageal squamous cell carcinoma. These properties make LINC00680 both a potential diagnostic biomarker and a therapeutic target in multiple disease contexts[2][4][6].

Other names
LINC00680
02

Mechanism of action

MicroRNA sponging (e.g., sponges miR-320a and miR-320b, affecting downstream targets such as MAPK1, EGR3, and PAK6); CeRNA network regulation

03

Biological functions

Competing endogenous RNA (ceRNA) activity—sponges specific microRNAs such as miR-320a and miR-320bRegulation of gene expression (post-transcriptional control, specifically modulates MAPK1 and EGR3 mRNA levels)Modulation of cellular proliferation and apoptosis
04

Disease associations

Cancer (glioblastoma, esophageal squamous cell carcinoma, soft-tissue sarcoma)Autoimmune disease (myasthenia gravis—regulated with disease severity)Other (potential roles in various disease syndromes via microRNA interaction; GWAS associations exist)
05

Safety considerations

No specific safety concerns described; as a non-coding RNA, off-target effects, delivery, and specificity are general challenges for RNA-based therapies
06

Biomarkers

Disease biomarker for severity in myasthenia gravisPrognostic biomarker in glioblastoma and soft-tissue sarcoma

Beyond the preview

Go deeper on Long intergenic non-protein coding RNA 680 (LINC00680).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Long intergenic non-protein coding RNA 680 (LINC00680).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call